Table 1. Demographics, Clinical Baseline Characteristics, and Time-Weighted Average Lipid and High-Sensitivity C-Reactive Protein Levelsa.
| Characteristic | Patients |
|---|---|
| Age, median (IQR), y | 60.3 (53.5-67.8) |
| Male | 3141 (73.8) |
| Body mass index, median (IQR)b | 29.3 (26.3-32.5) |
| Cardiovascular risk factors | |
| Hypertension | 3249 (77.1) |
| Diabetes | 1302 (30.7) |
| Hypercholesterolemia | 2127 (50.5) |
| Active smoker | 1429 (33.7) |
| Metabolic syndrome | 2674 (64.8) |
| Cardiovascular disease history | |
| Myocardial infarction | 1268 (30.0) |
| Percutaneous coronary intervention | 763 (18.0) |
| Coronary artery bypass graft surgery | 279 (6.6) |
| Stroke | 199 (4.7) |
| Peripheral arterial disease | 293 (6.9) |
| Previous lipid-modifying therapy | 1520 (35.8) |
| Index diagnosis | |
| ST–elevation myocardial infarction | 2025 (47.6) |
| Non-ST–elevation myocardial infarction | 1578 (37.1) |
| Unstable angina (biomarker negative) | 651 (15.3) |
| Index event to randomization, median (IQR), h | 56.6 (38.5-75.9) |
| Medications at randomization | |
| Aspirin | 3946 (92.7) |
| Clopidogrel, ticlopidine, or prasugrel | 3225 (75.8) |
| β-Blocker | 3594 (84.4) |
| ACEI or angiotensin receptor blocker | 3545 (83.3) |
| Concomitant atorvastatin dose | |
| 20 mg | 2059 (48.6) |
| 40 mg | 1470 (34.7) |
| 80 mg | 707 (16.7) |
| High-intensity statin therapyb | 707 (16.7) |
| Percutaneous coronary intervention for index event | 2677 (23.9) |
| Varespladib treatment | 2126 (49.9) |
| Baseline laboratory values, median (IQR), mg/dL | |
| High-density lipoprotein cholesterol level | 42.0 (36.0-49.0) |
| Low-density lipoprotein cholesterol level | 101.0 (75.0-131.0) |
| Non–high–density lipoprotein cholesterol level | 135.0 (105.0-171.0) |
| Triglyceride levels | 154.0 (115.0-211.0) |
| C-reactive protein level | 10.5 (4.2-30.3) |
| Time-weighted laboratory values after treatment, median (IQR), mg/dL | |
| High-density lipoprotein cholesterol level | 41.5 (35.5-48.7) |
| Low-density lipoprotein cholesterol level | 64.9 (50.3-82.3) |
| Non–high–density lipoprotein cholesterol level | 31.1 (73.7-111.0) |
| Triglyceride levels | 127.1 (98.4-167.8) |
| C-reactive protein level | 2.4 (1.1-5.2) |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; IQR, interquartile range.
a
Data are presented as number (percentage) of patients unless otherwise indicated.
b
Calculated as weight in kilograms divided by height in meters squared.
c
With a total daily dose of 80 mg of atorvastatin.